VTCN1 and breast cancer: When B7-H4 expression was stratified into high (top 33%) and low (bottom 33%) patient subgroups, high expression was associated with worse event-free survival (EFS) in chemotherapy-alone treated patients with early-stage breast cancer, which appeared to be overcome by anti-PD-1 combination therapy (Fig. 6E).